Search Results

Neuraly today announced the completion of patient enrollment in its Phase 2 study of NLY01 for Parkinson’s disease (PD).

Neuraly, a clinical stage biotechnology company pioneering disease-modifying agents for neurodegenerative disorders, today announced the dosing of the first patient in its Phase 2 clinical trial of NLY01 for Parkinson’s disease.

Maryland-based Neuraly surged forth from the startup gate with $36 million in Series A funding that will finance the company’s research into the development of therapies for neurodegenerative disorders.

NLY01 selectively blocks β-amyloid-induced activation of microglia through upregulated GLP-1R Neuronal viability was preserved, resulting in improved spatial learning and memory

Study recently published by Penn team in Cell Reports provides evidence that NLY01 has the potential for clinical use in the treatment of glaucoma and potentially other retinal diseases

Novel Mechanism of Action Inhibits Pathological Activation of Microglial Cells and Prevents Neuronal Cell Death

D&D Pharmatech, Inc., a clinical-stage biotechnology company focused on the development of disease-modifying drugs, announced that the U.S. Food and Drug Administration has granted Fast Track designation for the investigation of DD01 for the treatment of adults with non-alcoholic steatohepatitis, also known as metabolic dysfunction-associated steatohepatitis.

Novel Mechanism of Action Inhibits Pathological Activation of Microglial Cells and Prevents Neuronal Cell Death

Research published in Nature Medicine demonstrates protection against dopamine loss and behavioral deficits associated with Parkinson’s disease